APMA News - July/August 2024 - 58
IMPORTANT SAFETY INFORMATION (continued)
Warnings and Precautions
Hypersensitivity Reactions
Serious hypersensitivity (anaphylactic) and skin reactions have been reported with glycopeptide
antibacterial agents, including DALVANCE. Exercise caution in patients with known
hypersensitivity to glycopeptides due to the possibility of cross-sensitivity. If an allergic reaction
occurs, treatment with DALVANCE should be discontinued.
Infusion-related Reactions
Rapid intravenous infusion of DALVANCE can cause reactions, including flushing of the upper
body, urticaria, pruritus, rash, and/or back pain.
Hepatic Effects
ALT elevations with DALVANCE treatment were reported in clinical trials.
Clostridioides difficile-associated Diarrhea
Clostridioides difficile-associated diarrhea (CDAD) has been reported with nearly all systemic
antibacterial agents, including DALVANCE, with severity ranging from mild diarrhea to fatal
colitis. Evaluate if diarrhea occurs.
Development of Drug-resistant Bacteria
Prescribing DALVANCE in the absence of a proven or strongly suspected bacterial infection or a
prophylactic indication is unlikely to provide benefit to the patient and increases the risk of the
development of drug-resistant bacteria.
Adverse Reactions
The most common adverse reactions in adult patients treated with DALVANCE in Phase 2/3 trials
were nausea (5.5%), headache (4.7%), and diarrhea (4.4%). The most common adverse reaction
that occurred in more than 1% of pediatric patients was pyrexia (1.2%).
Use in Specific Populations
* There are no adequate and well-controlled studies with DALVANCE use in pregnant or nursing
women. The developmental and health benefits of breastfeeding should be considered along
with the mother's clinical need for DALVANCE and any adverse effects on the breast-fed child
from DALVANCE or from the underlying maternal condition.
* In patients with renal impairment whose known creatinine clearance (CLcr) is less than
30 mL/min and who are not receiving regularly scheduled hemodialysis, the recommended
regimen of DALVANCE is 1125 mg, administered as a single dose, or 750 mg followed one
week later by 375 mg. No dosage adjustment is recommended for patients receiving regularly
scheduled hemodialysis, and DALVANCE can be administered without regard to the timing of
hemodialysis. There is insufficient information to recommend dosage adjustment for pediatric
patients younger than 18 years of age with CLcr less than 30 mL/min/1.73m2
.
* Caution should be exercised when prescribing DALVANCE to patients with moderate or severe
hepatic impairment (Child-Pugh Class B or C) as no data are available to determine the
appropriate dosing in these patients.
Please see Brief Summary of full Prescribing Information on adjacent page or visit
https://www.rxabbvie.com/pdf/dalvance_pi.pdf
References: 1. DALVANCE®
(dalbavancin) [prescribing information]. Madison, NJ: Allergan USA, Inc.; 2021. 2. Data on file. AbbVie, Inc.
© 2024 AbbVie. All rights reserved. US-DAV-240002 01/24
DALVANCE®
and its design are trademarks of Allergan Pharmaceuticals International
Limited, an AbbVie company. Dalvance Connects® is a registered service mark of
Allergan Pharmaceuticals International Limited, an AbbVie company.
https://www.rxabbvie.com/pdf/dalvance_pi.pdf
APMA News - July/August 2024
Table of Contents for the Digital Edition of APMA News - July/August 2024
Contents
APMA News - July/August 2024 - Cover1
APMA News - July/August 2024 - Cover2
APMA News - July/August 2024 - 1
APMA News - July/August 2024 - 2
APMA News - July/August 2024 - 3
APMA News - July/August 2024 - 4
APMA News - July/August 2024 - Contents
APMA News - July/August 2024 - 6
APMA News - July/August 2024 - 7
APMA News - July/August 2024 - 8
APMA News - July/August 2024 - 9
APMA News - July/August 2024 - 10
APMA News - July/August 2024 - 11
APMA News - July/August 2024 - 12
APMA News - July/August 2024 - 13
APMA News - July/August 2024 - 14
APMA News - July/August 2024 - 15
APMA News - July/August 2024 - 16
APMA News - July/August 2024 - 17
APMA News - July/August 2024 - 18
APMA News - July/August 2024 - 19
APMA News - July/August 2024 - 20
APMA News - July/August 2024 - 21
APMA News - July/August 2024 - 22
APMA News - July/August 2024 - 23
APMA News - July/August 2024 - 24
APMA News - July/August 2024 - 25
APMA News - July/August 2024 - 26
APMA News - July/August 2024 - 27
APMA News - July/August 2024 - 28
APMA News - July/August 2024 - 29
APMA News - July/August 2024 - 30
APMA News - July/August 2024 - 31
APMA News - July/August 2024 - 32
APMA News - July/August 2024 - 33
APMA News - July/August 2024 - 34
APMA News - July/August 2024 - 35
APMA News - July/August 2024 - 36
APMA News - July/August 2024 - 37
APMA News - July/August 2024 - 38
APMA News - July/August 2024 - 39
APMA News - July/August 2024 - 40
APMA News - July/August 2024 - 41
APMA News - July/August 2024 - 42
APMA News - July/August 2024 - 43
APMA News - July/August 2024 - 44
APMA News - July/August 2024 - 45
APMA News - July/August 2024 - 46
APMA News - July/August 2024 - 47
APMA News - July/August 2024 - 48
APMA News - July/August 2024 - 49
APMA News - July/August 2024 - 50
APMA News - July/August 2024 - 51
APMA News - July/August 2024 - 52
APMA News - July/August 2024 - 53
APMA News - July/August 2024 - 54
APMA News - July/August 2024 - 55
APMA News - July/August 2024 - 56
APMA News - July/August 2024 - 57
APMA News - July/August 2024 - 58
APMA News - July/August 2024 - 59
APMA News - July/August 2024 - 60
APMA News - July/August 2024 - Cover3
APMA News - July/August 2024 - Cover4
APMA News - July/August 2024 - A1
APMA News - July/August 2024 - A2
APMA News - July/August 2024 - A3
APMA News - July/August 2024 - A4
https://www.nxtbook.com/nxtbooks/apma/news_20240910
https://www.nxtbook.com/nxtbooks/apma/news_20240708
https://www.nxtbook.com/nxtbooks/apma/news_20240506
https://www.nxtbook.com/nxtbooks/apma/news_20240304
https://www.nxtbook.com/nxtbooks/apma/news_20240102
https://www.nxtbook.com/nxtbooks/apma/news_20231112
https://www.nxtbook.com/nxtbooks/apma/news_20230910
https://www.nxtbook.com/nxtbooks/apma/news_20230708
https://www.nxtbook.com/nxtbooks/apma/news_20230506
https://www.nxtbook.com/nxtbooks/apma/news_20230304
https://www.nxtbook.com/nxtbooks/apma/news_20230102
https://www.nxtbook.com/nxtbooks/apma/news_20221112
https://www.nxtbook.com/nxtbooks/apma/news_20220910
https://www.nxtbook.com/nxtbooks/apma/news_20220708
https://www.nxtbook.com/nxtbooks/apma/news_20220506
https://www.nxtbook.com/nxtbooks/apma/news_20220304
https://www.nxtbook.com/nxtbooks/apma/news_20220102
https://www.nxtbook.com/nxtbooks/apma/news_20211112
https://www.nxtbook.com/nxtbooks/apma/news_20210910
https://www.nxtbook.com/nxtbooks/apma/news_20210708
https://www.nxtbook.com/nxtbooks/apma/news_20210506
https://www.nxtbook.com/nxtbooks/apma/news_20210304
https://www.nxtbook.com/nxtbooks/apma/news_20210102
https://www.nxtbook.com/nxtbooks/apma/news_20201112
https://www.nxtbook.com/nxtbooks/apma/news_20200910
https://www.nxtbook.com/nxtbooks/apma/news_20200708
https://www.nxtbook.com/nxtbooks/apma/news_20200506
https://www.nxtbook.com/nxtbooks/apma/news_20200304
https://www.nxtbook.com/nxtbooks/apma/news_20200102
https://www.nxtbook.com/nxtbooks/apma/news_20191112
https://www.nxtbook.com/nxtbooks/apma/news_20190910
https://www.nxtbook.com/nxtbooks/apma/news_20190708
https://www.nxtbook.com/nxtbooks/apma/news_20190506
https://www.nxtbook.com/nxtbooks/apma/news_20190304
https://www.nxtbook.com/nxtbooks/apma/news_20190102
https://www.nxtbook.com/nxtbooks/apma/news_20181112
https://www.nxtbook.com/nxtbooks/apma/news_20180910
https://www.nxtbook.com/nxtbooks/apma/news_20180708
https://www.nxtbook.com/nxtbooks/apma/news_20180506
https://www.nxtbook.com/nxtbooks/apma/news_20180304
https://www.nxtbook.com/nxtbooks/apma/news_20180102
https://www.nxtbook.com/nxtbooks/apma/news_20171112
https://www.nxtbook.com/nxtbooks/apma/news_20170910
https://www.nxtbook.com/nxtbooks/apma/news_20170708
https://www.nxtbook.com/nxtbooks/apma/news_20170506
https://www.nxtbook.com/nxtbooks/apma/news_20170304
https://www.nxtbook.com/nxtbooks/apma/news_20170102
https://www.nxtbook.com/nxtbooks/apma/news_20161112
https://www.nxtbook.com/nxtbooks/apma/news_20160910
https://www.nxtbook.com/nxtbooks/apma/news_20160708
https://www.nxtbook.com/nxtbooks/apma/news_20160506
https://www.nxtbook.com/nxtbooks/apma/news_20160304
https://www.nxtbook.com/nxtbooks/apma/news_20160102
https://www.nxtbook.com/nxtbooks/apma/news_20151112
https://www.nxtbook.com/nxtbooks/apma/news_20150910
https://www.nxtbook.com/nxtbooks/apma/news_20150708
https://www.nxtbook.com/nxtbooks/apma/news_201506
https://www.nxtbook.com/nxtbooks/apma/news_201505
https://www.nxtbook.com/nxtbooks/apma/news_201504
https://www.nxtbook.com/nxtbooks/apma/news_201503
https://www.nxtbook.com/nxtbooks/apma/news_201502
https://www.nxtbook.com/nxtbooks/apma/news_201501
https://www.nxtbook.com/nxtbooks/apma/news_20141112
https://www.nxtbook.com/nxtbooks/apma/news_201410
https://www.nxtbook.com/nxtbooks/apma/news_201409
https://www.nxtbook.com/nxtbooks/apma/news_20140708
https://www.nxtbook.com/nxtbooks/apma/news_201406
https://www.nxtbook.com/nxtbooks/apma/news_201405
https://www.nxtbook.com/nxtbooks/apma/news_201404
https://www.nxtbook.com/nxtbooks/apma/news_201403
https://www.nxtbook.com/nxtbooks/apma/news_201402
https://www.nxtbook.com/nxtbooks/apma/news_201401
https://www.nxtbook.com/nxtbooks/apma/news_201311
https://www.nxtbook.com/nxtbooks/apma/news_201310
https://www.nxtbook.com/nxtbooks/apma/news_201309
https://www.nxtbook.com/nxtbooks/apma/news_201308
https://www.nxtbook.com/nxtbooks/apma/news_201306
https://www.nxtbook.com/nxtbooks/apma/news_201305
https://www.nxtbook.com/nxtbooks/apma/news_201304
https://www.nxtbook.com/nxtbooks/apma/news_201303
https://www.nxtbook.com/nxtbooks/apma/news_201302
https://www.nxtbook.com/nxtbooks/apma/news_201301
https://www.nxtbook.com/nxtbooks/apma/news_201211
https://www.nxtbook.com/nxtbooks/apma/news_201210
https://www.nxtbook.com/nxtbooks/apma/news_201209
https://www.nxtbook.com/nxtbooks/apma/news_20120708
https://www.nxtbook.com/nxtbooks/apma/news_201206
https://www.nxtbook.com/nxtbooks/apma/news_201205
https://www.nxtbook.com/nxtbooks/apma/news_201204
https://www.nxtbook.com/nxtbooks/apma/news_201203
https://www.nxtbook.com/nxtbooks/apma/news_201202
https://www.nxtbook.com/nxtbooks/apma/news_201201
https://www.nxtbook.com/nxtbooks/apma/news_201111
https://www.nxtbook.com/nxtbooks/apma/news_201110
https://www.nxtbook.com/nxtbooks/apma/news_201109
https://www.nxtbook.com/nxtbooks/apma/news_201107
https://www.nxtbook.com/nxtbooks/apma/news_201106
https://www.nxtbook.com/nxtbooks/apma/news_201105
https://www.nxtbook.com/nxtbooks/apma/news_201104
https://www.nxtbook.com/nxtbooks/apma/news_201103
https://www.nxtbook.com/nxtbooks/apma/news_201102
https://www.nxtbookmedia.com